Oral azacitidine compared with standard therapy in patients with relapsed or refractory follicular helper T-cell lymphoma (ORACLE): an open-label randomised, phase 3 study.
Fiche publication
Date publication
juin 2024
Journal
The Lancet. Haematology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr CASASNOVAS Olivier, Pr FORNECKER Luc-Matthieu
Tous les auteurs :
Dupuis J, Bachy E, Morschhauser F, Cartron G, Fukuhara N, Daguindau N, Casasnovas RO, Snauwaert S, Gressin R, Fox CP, d'Amore FA, Staber PB, Tournilhac O, Bouabdallah K, Thieblemont C, André M, Rai S, Ennishi D, Gkasiamis A, Nishio M, Fornecker LM, Delfau-Larue MH, Sako N, Mule S, de Leval L, Gaulard P, Tsukasaki K, Lemonnier F
Lien Pubmed
Résumé
Follicular helper T-cell lymphomas (TFHL) harbour frequent alterations in genes that regulate DNA methylation. Preliminary reports suggest that treatment with 5-azacitidine has clinical activity in patients with relapsed or refractory TFHL. We aimed to compare the oral form of azacitidine with investigator's choice standard therapy (ICT; ie, gemcitabine, bendamustine, or romidepsin) in patients with relapsed or refractory TFHL.
Mots clés
Humans, Male, Female, Aged, Middle Aged, Azacitidine, therapeutic use, Administration, Oral, Bendamustine Hydrochloride, therapeutic use, Gemcitabine, Lymphoma, Follicular, drug therapy, Deoxycytidine, analogs & derivatives, Depsipeptides, therapeutic use, Antineoplastic Combined Chemotherapy Protocols, therapeutic use, Antimetabolites, Antineoplastic, therapeutic use, Aged, 80 and over
Référence
Lancet Haematol. 2024 06;11(6):e406-e414